Overall survival of Non-Hodgkin lymphoma in HIV-infected patients at Siriraj Hospital
Keywords:
-Abstract
-
Downloads
Download data is not yet available.
References
References
1. Noy A. Optimizing treatment for HIV-associated lymphoma. Blood.2019. [Epub ahead of print]
2. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241-8.
3. Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28:2313-8.
4. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G, et al. North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate
AIDS. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163:507-18.
5. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby- Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated
in the rituximab era. Blood. 2014;123:837-42.
6. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1,546 patients. Blood. 2013;122;3251-62.
7. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab
in patients with HIV-associated non-Hodgkin lymphoma: AIDS Malignancies Consortium Trial 010. Blood. 2005;106:1538-43
1. Noy A. Optimizing treatment for HIV-associated lymphoma. Blood.2019. [Epub ahead of print]
2. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241-8.
3. Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28:2313-8.
4. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G, et al. North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate
AIDS. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163:507-18.
5. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby- Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated
in the rituximab era. Blood. 2014;123:837-42.
6. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1,546 patients. Blood. 2013;122;3251-62.
7. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab
in patients with HIV-associated non-Hodgkin lymphoma: AIDS Malignancies Consortium Trial 010. Blood. 2005;106:1538-43
Downloads
Published
2019-12-20
Issue
Section
บทบรรณาธิการ (Editorial)
